IN2012DN05142A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN05142A IN2012DN05142A IN5142DEN2012A IN2012DN05142A IN 2012DN05142 A IN2012DN05142 A IN 2012DN05142A IN 5142DEN2012 A IN5142DEN2012 A IN 5142DEN2012A IN 2012DN05142 A IN2012DN05142 A IN 2012DN05142A
- Authority
- IN
- India
- Prior art keywords
- crystalline forms
- pentanamide
- amino
- methyl
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26067109P | 2009-11-12 | 2009-11-12 | |
US29427910P | 2010-01-12 | 2010-01-12 | |
US35079710P | 2010-06-02 | 2010-06-02 | |
PCT/US2010/056537 WO2011060262A1 (en) | 2009-11-12 | 2010-11-12 | Crystalline forms of neurotrophin mimetic compounds and their salts |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN05142A true IN2012DN05142A (de) | 2015-10-23 |
Family
ID=43992064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN5142DEN2012 IN2012DN05142A (de) | 2009-11-12 | 2010-11-12 |
Country Status (10)
Country | Link |
---|---|
US (3) | US9271986B2 (de) |
EP (2) | EP3470402B1 (de) |
JP (3) | JP5863663B2 (de) |
CN (3) | CN108383804A (de) |
AU (1) | AU2010319349B2 (de) |
CA (2) | CA2780940C (de) |
ES (1) | ES2712752T3 (de) |
HK (1) | HK1212970A1 (de) |
IN (1) | IN2012DN05142A (de) |
WO (1) | WO2011060262A1 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5863663B2 (ja) | 2009-11-12 | 2016-02-16 | ファーマトロフィックス, インコーポレイテッド | ニューロトロフィン模倣化合物およびこれらの塩の結晶形態 |
US10273219B2 (en) | 2009-11-12 | 2019-04-30 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
EP2900646A4 (de) * | 2012-09-27 | 2016-09-21 | Pharmatrophix Inc | Kristalline formen aus neurotrophinmimetischen verbindungen und deren salzen |
EP3302104B1 (de) * | 2015-06-04 | 2020-09-30 | Balchem Corporation | Hydrierungssteuerung für cholinsalze |
US11215532B2 (en) | 2020-05-04 | 2022-01-04 | Ford Global Technologies, Llc | Methods and systems for exhaust gas recirculation system diagnostics |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3541130A (en) | 1967-02-06 | 1970-11-17 | Boehringer Sohn Ingelheim | 1-(cyanophenoxy)-2-hydroxy-3-tert.-butylamine propanes |
US4613676A (en) | 1983-11-23 | 1986-09-23 | Ciba-Geigy Corporation | Substituted 5-amino-4-hydroxyvaleryl derivatives |
US4743607A (en) | 1987-05-29 | 1988-05-10 | Merrell Dow Pharmaceuticals Inc. | Cardiotonic tricyclic imidazolones |
EP0413751A4 (en) | 1988-05-02 | 1992-07-22 | N. Eric Naftchi | Neurologically active compounds |
US5028622A (en) | 1988-05-06 | 1991-07-02 | Ajinomoto Company, Inc. | Administration of amino acids as treatment for neurodegenerative disorders |
US5321029A (en) | 1988-11-14 | 1994-06-14 | Beecham-Wuelfing Gmbh & Co.K.G. | Xanthines |
CA2010531A1 (en) * | 1989-03-06 | 1990-09-06 | Werner Neidhart | Amino acid derivatives |
DE59205565D1 (de) | 1991-10-07 | 1996-04-11 | Hoechst Ag | Carbonsäureester-Schutzgruppen, ein Verfahren zu ihrer Herstellung, ihre Kopplung an eine funktionelle Gruppe sowie ihre Verwendung |
US5608067A (en) | 1993-12-09 | 1997-03-04 | Afonso; Adriano | 4-substituted pyrazoloquinoline derivatives |
GB9402331D0 (en) | 1994-02-07 | 1994-03-30 | Univ Mcgill | Nerve growth factor structural analogs and their uses |
JPH08119922A (ja) | 1994-10-21 | 1996-05-14 | Torii Yakuhin Kk | o−ピバロイル−チロシン誘導体 |
WO1996016980A1 (en) * | 1994-11-29 | 1996-06-06 | Novartis Ag | Morpholinoethylamide derivatives |
JPH1081661A (ja) | 1995-10-23 | 1998-03-31 | Sankyo Co Ltd | ヒドロキサム酸誘導体 |
WO1997037228A1 (en) | 1996-03-29 | 1997-10-09 | The Trustees Of Boston University | Methods for diagnosing and treating alzheimer's disease |
US5958875A (en) | 1996-03-29 | 1999-09-28 | The Regents Of The University Of California | Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity |
WO1997042168A1 (en) | 1996-05-06 | 1997-11-13 | Zeneca Limited | Thio derivatives of hydroxamic acids |
GB9613547D0 (en) | 1996-06-27 | 1996-08-28 | Pharmacia Spa | Matrix metalloproteinase inhibitors |
GB9616105D0 (en) | 1996-07-31 | 1996-09-11 | Univ Kingston | TrkA binding site of NGF |
GB9715962D0 (en) | 1996-08-23 | 1997-10-01 | Zeneca Ltd | Sulfonamides |
DE69836422T2 (de) | 1997-02-19 | 2007-06-14 | Berlex, Inc., Richmond | N-heterocyclische derivate als nos inhibitoren |
FR2762315B1 (fr) | 1997-04-22 | 1999-05-28 | Logeais Labor Jacques | Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha |
US6117841A (en) | 1997-05-30 | 2000-09-12 | Warner-Lambert Company | Substituted peptidylamine calcium channel blockers |
US6342507B1 (en) | 1997-09-05 | 2002-01-29 | Isotechnika, Inc. | Deuterated rapamycin compounds, method and uses thereof |
US20020022657A1 (en) | 1998-02-11 | 2002-02-21 | Francine Gervais | Methods for modulating neuronal cell death |
WO1999050264A1 (fr) | 1998-03-30 | 1999-10-07 | Kyowa Hakko Kogyo Co., Ltd. | Derives de quinazoline |
FR2783519B1 (fr) | 1998-09-23 | 2003-01-24 | Sod Conseils Rech Applic | Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
KR20010100983A (ko) | 1998-11-06 | 2001-11-14 | 로셰 디아그노스틱스 게엠베하 | 매트릭스 메탈로프로테아제 관련 질환 치료제용 시스틴유도체 |
WO2000037462A1 (en) | 1998-12-18 | 2000-06-29 | Warner-Lambert Company | Non-peptide nk1 receptors antagonists |
US6583148B1 (en) | 1999-04-08 | 2003-06-24 | Krenitsky Pharmaceuticals, Inc. | Neurotrophic substituted pyrimidines |
US6492380B1 (en) | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
TWI275587B (en) | 1999-06-17 | 2007-03-11 | Takeda Chemical Industries Ltd | A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
US6858577B1 (en) | 1999-06-29 | 2005-02-22 | Ortho-Mcneil Pharmaceutical, Inc. | Indole peptidomimetics as thrombin receptor antagonists |
DE19939910A1 (de) | 1999-08-23 | 2001-03-01 | Morphochem Ag | Neue Verbindungen, die Tryptase-Aktivität hemmen |
AU7353300A (en) | 1999-09-08 | 2001-04-10 | Guilford Pharmaceuticals Inc. | Non-peptidic cyclophilin binding compounds and their use |
DE60032016T2 (de) | 1999-12-08 | 2007-06-21 | Teijin Ltd. | Cycloamin-ccr5-rezeptor-antagonisten |
ES2273849T3 (es) | 2000-01-18 | 2007-05-16 | Mcgill University | Composiciones farmaceuticas que comprenden compuestos ciclicos peptidometicos con giro beta. |
AR028606A1 (es) | 2000-05-24 | 2003-05-14 | Smithkline Beecham Corp | Nuevos inhibidores de mmp-2/mmp-9 |
US6699989B1 (en) | 2000-08-28 | 2004-03-02 | B. Vithal Shetty | Antiviral and antimicrobial guanidine or biguanidine derivatives |
WO2002048660A1 (en) | 2000-12-13 | 2002-06-20 | Spelman College | Multiplex coherent raman spectroscopy detector and method |
NZ530646A (en) | 2001-07-11 | 2008-01-31 | Upjohn Co | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds |
US20040248984A1 (en) | 2001-08-29 | 2004-12-09 | Josef Krieglstein | Use of $g(b)-adrenoceptor agonists for the treatment of neurodegenerative diseases |
WO2003030836A2 (en) | 2001-10-12 | 2003-04-17 | Case Western Reserve University | Neuronal regeneration |
JP2005520791A (ja) | 2001-11-08 | 2005-07-14 | イーラン ファーマスーティカルズ、インコーポレイテッド | N,n’−置換−1,3−ジアミノ−2−ヒドロキシプロパン誘導体 |
CN1662506A (zh) * | 2002-05-03 | 2005-08-31 | 以色列生物研究所 | 治疗中枢和周围神经系统疾病的方法和组合物及其有用的新化合物 |
UA77526C2 (en) | 2002-06-07 | 2006-12-15 | Sanofi Aventis | Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy |
WO2004028466A2 (en) | 2002-09-25 | 2004-04-08 | Georiga Tech Research Corporation | Ketoamide inhibitors in chronic nerve disease |
US20040077635A1 (en) | 2002-10-02 | 2004-04-22 | Qiao Jennifer X. | Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor Xa inhibitors |
US20040186044A1 (en) | 2002-11-06 | 2004-09-23 | Cosgaya Jose Miguel | Modulation of myelination by interaction with P75 and TRK receptors |
US20050154011A1 (en) | 2003-02-20 | 2005-07-14 | The Procter & Gamble Company | Tetrahydroisoquinolnyl sulfamic acids |
GB0304433D0 (en) | 2003-02-27 | 2003-04-02 | Xceleron Ltd | Improvements relating to chemical libraries |
US7202269B2 (en) | 2003-10-30 | 2007-04-10 | Janssen Pharmaceutica N.V. | GlyT2 modulators |
EP1689721B1 (de) | 2003-11-26 | 2010-07-14 | Pfizer Products Inc. | Aminopyrazolderivate als gsk-3-inhibitoren |
EP1729755A1 (de) | 2004-01-21 | 2006-12-13 | Elan Pharmaceuticals, Inc. | Verfahren zur behandlung von amyloidosis mit aspartyl-protease-hemmern |
WO2005095327A1 (ja) | 2004-03-31 | 2005-10-13 | Ajinomoto Co., Inc. | アニリン誘導体 |
WO2006005941A1 (en) | 2004-07-12 | 2006-01-19 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. | Amide derivatives as inhibitors of histone deacetylase |
JP4194540B2 (ja) | 2004-07-27 | 2008-12-10 | キヤノン株式会社 | 画像形成装置 |
US20110230479A1 (en) | 2005-04-15 | 2011-09-22 | Longo Frank M | Neurotrophin mimetics and uses thereof |
US7723328B2 (en) * | 2005-04-15 | 2010-05-25 | The University Of North Carolina At Chapel Hill | Methods of facilitating cell survival using neurotrophin mimetics |
US8686045B2 (en) | 2005-06-08 | 2014-04-01 | The University Of North Carolina At Chapel Hill | Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics |
CN101384261B (zh) | 2005-12-22 | 2011-12-07 | 海德拉生物科学公司 | 治疗疼痛的组合物 |
WO2008107365A1 (en) | 2007-03-02 | 2008-09-12 | Medivir Ab | New compounds |
JP2012519703A (ja) | 2009-03-06 | 2012-08-30 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | ニューロトロフィン・ミメティック及びその使用 |
US10273219B2 (en) | 2009-11-12 | 2019-04-30 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
JP5863663B2 (ja) | 2009-11-12 | 2016-02-16 | ファーマトロフィックス, インコーポレイテッド | ニューロトロフィン模倣化合物およびこれらの塩の結晶形態 |
US20120322799A1 (en) | 2009-11-30 | 2012-12-20 | Pharmatrophix, Inc. | Deuterated compounds useful for treating neurodegenerative diseases |
EP2900646A4 (de) | 2012-09-27 | 2016-09-21 | Pharmatrophix Inc | Kristalline formen aus neurotrophinmimetischen verbindungen und deren salzen |
-
2010
- 2010-11-12 JP JP2012539022A patent/JP5863663B2/ja active Active
- 2010-11-12 CA CA2780940A patent/CA2780940C/en active Active
- 2010-11-12 CN CN201810315680.4A patent/CN108383804A/zh active Pending
- 2010-11-12 WO PCT/US2010/056537 patent/WO2011060262A1/en active Application Filing
- 2010-11-12 CN CN201510017717.1A patent/CN104761515B/zh active Active
- 2010-11-12 CN CN201080060921.7A patent/CN102740856B/zh active Active
- 2010-11-12 EP EP18207630.7A patent/EP3470402B1/de active Active
- 2010-11-12 US US13/509,470 patent/US9271986B2/en active Active
- 2010-11-12 IN IN5142DEN2012 patent/IN2012DN05142A/en unknown
- 2010-11-12 CA CA3125909A patent/CA3125909C/en active Active
- 2010-11-12 AU AU2010319349A patent/AU2010319349B2/en not_active Ceased
- 2010-11-12 EP EP10830787.7A patent/EP2498782B1/de active Active
- 2010-11-12 ES ES10830787T patent/ES2712752T3/es active Active
-
2013
- 2013-04-16 HK HK16100194.6A patent/HK1212970A1/zh unknown
-
2015
- 2015-10-09 JP JP2015200793A patent/JP2016020380A/ja active Pending
- 2015-12-17 US US14/972,506 patent/US20160176832A1/en not_active Abandoned
-
2017
- 2017-08-21 US US15/682,389 patent/US10532988B2/en active Active
-
2018
- 2018-05-07 JP JP2018089165A patent/JP6657294B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
CA3125909A1 (en) | 2011-05-19 |
HK1212970A1 (zh) | 2016-06-24 |
EP2498782A1 (de) | 2012-09-19 |
JP6657294B2 (ja) | 2020-03-04 |
AU2010319349A1 (en) | 2012-07-05 |
CN104761515A (zh) | 2015-07-08 |
CA2780940A1 (en) | 2011-05-19 |
EP2498782B1 (de) | 2019-01-09 |
US9271986B2 (en) | 2016-03-01 |
CN102740856B (zh) | 2015-02-18 |
AU2010319349B2 (en) | 2015-07-16 |
JP5863663B2 (ja) | 2016-02-16 |
CN104761515B (zh) | 2018-03-09 |
EP3470402A1 (de) | 2019-04-17 |
US20180037559A1 (en) | 2018-02-08 |
JP2018115218A (ja) | 2018-07-26 |
CA2780940C (en) | 2021-08-31 |
CN108383804A (zh) | 2018-08-10 |
CA3125909C (en) | 2023-10-31 |
CN102740856A (zh) | 2012-10-17 |
US20160176832A1 (en) | 2016-06-23 |
JP2013510874A (ja) | 2013-03-28 |
EP2498782A4 (de) | 2014-03-12 |
US20130005731A1 (en) | 2013-01-03 |
WO2011060262A1 (en) | 2011-05-19 |
JP2016020380A (ja) | 2016-02-04 |
US10532988B2 (en) | 2020-01-14 |
EP3470402B1 (de) | 2021-01-06 |
ES2712752T3 (es) | 2019-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY181898A (en) | Heterocyclic compounds and uses thereof | |
SG179085A1 (en) | Pi3 kinase inhibitors and uses thereof | |
MX338489B (es) | Derivados de hidantoina utiles como inhibidores de kv3. | |
TN2011000673A1 (en) | Bace inhibitors | |
MX341825B (es) | Compuestos de heteroarilo y usos de los mismos. | |
MX2011007930A (es) | Conjugados de insulina cristalina. | |
IN2012DN03883A (de) | ||
PH12014501273A1 (en) | Intranasal dexmedetomidine compositions and methods of use thereof | |
MX2009008347A (es) | Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso. | |
TR201813877T4 (tr) | Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler. | |
MX2012007098A (es) | Derivados fenolicos y su uso farmaceutico o cosmetico. | |
HK1154002A1 (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
JO2892B1 (en) | CYP inhibitors 17 | |
MX2012007161A (es) | Derivados fenolicos y su uso farmaceutico o cosmetico. | |
MX2009008430A (es) | Anticuerpos anti-robo4 y sus usos. | |
TW201713640A (en) | Bruton's tyrosine kinase inhibitors | |
WO2011032169A3 (en) | Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same | |
UA104885C2 (uk) | Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів | |
MX2011014019A (es) | Derivados de diazahomoadamantano y sus metodos de uso. | |
MX2012004780A (es) | Inhibidores de akt. | |
JO3755B1 (ar) | تركيبات تستوستيرون | |
MX2013002851A (es) | Inhibidores de tonum pectinacetilesterasa y metodos de su uso. | |
MX2011012533A (es) | Espiro-epoxidos como productos intermedios. | |
IN2012DN03404A (de) | ||
IN2012DN05142A (de) |